Core Insights - Third Coast Bancshares, Inc. reported a net income of $18.1 million for Q3 2025, an increase from $16.7 million in Q3 2024, resulting in a basic EPS of $1.22 and a diluted EPS of $1.03 [1][7] - The increase in net income was primarily driven by stronger net interest income and higher non-margin loan fees, although it was partially offset by a higher provision for credit losses [1][7] - The company is expected to maintain operational efficiency through a 1% improvement initiative, with non-interest expenses projected to remain stable [1] Financial Performance - Net income for Q3 2025 rose to $18.1 million, with a return on average assets (ROAA) improving to 1.41% from 1.38% sequentially [7] - The net interest margin for Q3 2025 was reported at 4.10%, compared to 4.22% in Q2 2025 and 3.73% year-over-year [7] Strategic Developments - Third Coast Bancshares announced a definitive agreement to acquire Keystone Bancshares for approximately $123 million, with pro forma assets exceeding $6 billion and a targeted closing in Q1 2026 [7]

Group 1 - Stonegate Capital Partners has initiated coverage on Pensana PLC, highlighting its unique position as one of the few developers outside China pursuing a full mine-to-magnet model in the rare earth supply chain [1][6] - Pensana is advancing a U.S.-facing downstream strategy that aligns with Western supply chain security goals, moving away from a traditional "dig-and-ship" approach [1][6] - The company has established a memorandum of understanding with ReElement Technologies, which provides a direct pathway for Longonjo feedstock to be refined and separated in the United States, linking production to magnet manufacturing [1][6] Group 2 - Offtake agreements and memorandums of understanding already cover multiples of Stage 1 capacity, indicating strong demand for Pensana's high-specification product [1][6] - Longonjo is fully financed and under construction, with Stage 1 expected to produce approximately 20,000 tonnes of MREC in 2026, increasing to around 40,000 tonnes in 2027, benefiting from the Lobito rail and hydro power [1][6] - Pensana's strategy aligns with U.S. 2027 magnet-supply objectives, and management is considering a potential Nasdaq uplisting to enhance institutional access and trading liquidity [1][6]

Core Insights - Stonegate Capital Partners has initiated coverage on Heliostar Metals Ltd (TSXV: HSTR), highlighting the company's flagship Ana Paula project in Guerrero, which hosts approximately 1.2 million ounces of gold at a grade of 5.4 g/t in the High-Grade Panel [1] - Active drilling is ongoing to extend the Parallel Panel and upgrade inferred ounces, with a preliminary economic assessment currently underway, followed by a feasibility study expected in mid-2026 [1] - The company targets first production in 2028 and is fully permitted for open-pit mining, with plans to submit an underground permit amendment in 2026 [1] Financial Performance - Heliostar Metals Ltd sold 8,556 gold equivalent ounces (GEOs) at an all-in sustaining cost (AISC) of US$1,541 per ounce, generating revenue of $27.9 million [6] - The company has approximately $30.0 million in cash and no debt [6] - In the second quarter of 2025, La Colorada produced 3,464 ounces at low costs, while San Agustin received approval to restart mining in the fourth quarter of 2025 [6] Project Development - The Ana Paula drilling is advancing towards a 2026 Preliminary Feasibility Study (PFS), with a production target of approximately 100,000 ounces per year starting in 2028 [6]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production [5]

Stonegate Capital Partners Initiates Coverage on Medicus Pharma Ltd. (MDCX)September 24, 2025 9:26 AM EDT | Source: Reportable, Inc. Dallas, Texas--(Newsfile Corp. - September 24, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX): Stonegate Capital Partners initiates their coverage on Medicus Pharma Ltd. (NASDAQ: MDCX). Medicus advanced several strategic initiatives in 2Q25 as it builds a diversified portfolio of clinical and pre-clinical assets. The Company completed the acquisition of Antev Limited ...

Group 1 - Stonegate Capital Partners has initiated coverage on Seabridge Gold Inc. (NYSE: SA) as of September 15, 2025 [1] - As of Q2 2025, Seabridge Gold reported cash and cash equivalents of $121.4 million, bolstered by a $100.2 million equity financing in February 2025 and a $30.5 million flow-through financing in June 2025 [1] - The company is focused on advancing its flagship KSM project and exploration at Iskut, 3 Aces, and Snowstorm [1] Group 2 - Seabridge Gold renewed its $750 million base shelf prospectus and $100 million ATM facility in early 2025 [1] - The company reported a Q2 net profit of $12.3 million ($0.12/share), a decrease from $45.2 million in Q2 2024, primarily due to the remeasurement of secured note liabilities [8] - Seabridge invested $21.1 million into projects during the quarter, and drilling at Iskut's Snip North confirmed a large copper-gold porphyry deposit, with a maiden resource estimate expected in early 2026 [8]

Core Insights - Stonegate Capital Partners has initiated coverage on Provident Financial Services Inc (NYSE: PFS) [1] - For Q2 2025, Provident Financial Services reported a net income of $72.0 million, an increase from $64.0 million in Q1 2025, and a significant recovery from a net loss of $11.5 million in Q2 2024 [1][7] - The earnings per share (EPS) for Q2 2025 was $0.55, compared to $0.49 in Q1 2025 [1][7] - The increase in net income was attributed to higher net interest income from new loan originations and improved repricing on adjustable-rate loans, despite higher compensation expenses and lower average low-cost deposits [1][7] Financial Performance - Provident Financial Services achieved record revenue of $214.2 million in Q2 2025, supported by net interest income of $187.1 million and non-interest income of $27.1 million [7] - Commercial loan balances increased by $319.3 million during the quarter [7] - The company maintained strong credit quality, with non-performing assets improving to just 0.44% of total assets [7]

Core Insights - Aquafil Group (MI: ECNL) demonstrated strong profitability in Q2 2025 despite modest revenue declines, achieving an EBITDA margin of 15.5%, up from 12.3% in Q2 2024 [1][7] - The company's ECONYL® products were crucial, accounting for 60.7% of fiber revenues in Q2 2025, aligning with its long-term sustainability strategy [1][7] - The U.S. BCF segment experienced double-digit growth, while EMEA remained stable and APAC showed softness [1] - A significant cost-optimization project was launched in U.S. carpet recycling operations, with expected initial savings in H2 2025 and more substantial benefits in 2026 and beyond [1] Financial Performance - EBITDA rose by 22.7% to $21.3 million compared to $17.3 million in Q2 2024 [7] - The net profit was $1.8 million, reversing a loss of $3.0 million in Q2 2024 [7]

Core Insights - Cingulate Inc. is making significant progress towards the commercial launch of its lead ADHD asset, CTx-1301, with a focus on its Precision Timed Release (PTR) platform designed for once-daily dosing [1][5]. Financial Performance - Cingulate reported $8.9 million in cash and $3.5 million in working capital at the end of 2Q25, which is expected to fund operations into late 2025 [5]. Product Development - The company submitted its New Drug Application (NDA) for CTx-1301 on July 31, 2025, with FDA acceptance anticipated in 4Q25 and a potential PDUFA date in mid-2026 [5]. - Positive results from the Phase 3 pediatric trial and fed/fast study have reinforced CTx-1301's efficacy and flexible dosing capabilities [5]. Commercialization Strategy - Cingulate is actively planning for commercialization in collaboration with Indegene, aiming for a product launch in mid-2026 [5]. - The company is also exploring strategic partnerships to expand its global presence [1].

Core Insights - Stonegate Capital Partners has initiated coverage on American Tungsten Corp. (CSE: TUNG) [1] Financial Performance - In Q1 2025, American Tungsten Corp. reported a net loss of C$1.87 million, compared to a net loss of C$63.7 thousand in Q1 2024, indicating a significant increase in losses [1][5] - Total assets increased to C$2.36 million from C$1.46 million in Q4 2024, primarily due to a higher cash balance of C$1.25 million following a multi-tranche private placement [1] - Shareholders' equity more than doubled to C$2.04 million, and the company remains debt-free, providing flexibility for ongoing exploration [1] Expenditures - Key expenses included C$663.6 thousand for investor relations, C$191.3 thousand for exploration and evaluation, and C$461.8 thousand for professional fees, reflecting the company's aggressive strategy to advance its flagship U.S.-based project [1][5]